|
|
Distribution of genetic predisposition and past history of
cancer in 9672 patients with primary central nervous system tumors Herbert H. Engelhard III, Kimberly R. Porter, Andrew K.
Stewart, Jeffrey J. Olson
University of Illinois, Chicago, Chicago, IL,
American College of Surgeons, Chicago, IL, Emory University, Atlanta, GA. E-mail:
hhengel@uic.edu
Background.
During the year 2000, extensive data on 9672 patients diagnosed to
have a primary neoplasm of the central nervous system (CNS) were collected in a
hospital-based study conducted by the Commission on Cancer of the American
College of Surgeons.
One of the objectives of the study was to determine the
percentages of CNS tumor patients having a past history of another cancer (or
tumor), and/or a family history of a genetic syndrome known to be associated
with CNS tumors (i.e. "genetic predisposition").
The purpose of
this presentation is to report on the results of this portion of the study.Methods.
Data were collected from 604 participating hospitals, via electronic
record submissions made directly to the National Cancer Data Base and/or on
scannable paper forms.
Eligible cases were selected based on the ICD-O-2
topography codes C70.0-C70.9 (meninges), C71.0-C71.9 (brain), C72.0-C72.9
(spinal cord, cranial nerves and other parts of the CNS), and C75.1-C75.3
(pituitary, craniopharyngeal and pineal glands).
All data were analyzed using
SPSSł, a standard statistical software package.
Results.
Overall, the 9672 patients ranged in age from 1 to 104 years, with a
mean age of 55.34 years.
95.6% had intracranial tumors.
12.1% of the patients
were found to have a personal history of previous cancer, and 1.4% of patients
had a family history of a recognized genetic syndrome according to the following
breakdown:
109 patients had a past history of more than one type of cancer or tumor.
9
patients had a family history of more than one genetic syndrome.
Cross-tabulation of the data from the study links patients in the subsets above
to a large number of other variables such as gender, race, symptoms, signs,
history of other diseases, methods of diagnosis, treatment, performance status
and histology.
Conclusions.
To date, the Surveillance, Epidemiology, and End Results (SEER)
Program has been the primary source for U.S. data on other cancers occuring in
patients with brain tumors.
Our study is hospital-based, not population-based,
and therefore may be susceptible to selection bias.
The two databases differ in
the information that they contain; each has significant value and can be used to
generate testable hypotheses.
Information related to tumor recurrence and
survival will continue to be tracked for the patients entered into this study.
Copyright © 2004 American Association for Cancer Research. All rights
reserved.
Source: http://aacr04.agora.com/planner/displayabstract.asp?presentationid=2927
|
